#pharmaceutical

Empresas biofarmacêuticas estão reestruturando acordos de licença internacionais para reduzir sua exposição às regras de precificação da Nação Mais Favorecida, que vinculam preços de medicamentos dos EUA aos preços mais baixos pagos em outros países.

Ugur Sahin and Ozlem Tureci will exit BioNTech by year-end to start a company focused on next-generation mRNA innovations.

Pharmaceutical giant GSK has agreed to buy 35Pharma, a biotech focused on pulmonary hypertension, for $950 million. The deal expands GSK's respiratory and cardiovascular portfolio with a pipeline targeting a disease that currently has limited treatment options.

Novo Nordisk has struck a deal with Vivtex, a biotech co-founded by MIT professor Robert Langer, to develop oral versions of obesity and diabetes treatments. The partnership could eliminate the need for weekly injections that have defined the GLP-1 drug revolution.